Posts Tagged ‘preserved ejection fraction’

November 24th, 2014

Selections from Richard Lehman’s Literature Review: November 24th

This week’s topics include the PROTECT-AF trial, the association of inpatient vs. outpatient onset of STEMI with treatment and clinical outcomes, and more.

April 14th, 2014

Selections from Richard Lehman’s Literature Review: April 14th

This week’s topics include TOPCAT, fibrinolysis for those with intermediate-risk PE, and more.

March 12th, 2013

Sildenafil Does Not Improve Exercise Capacity in HF with Preserved Ejection Fraction

Sildenafil does not improve exercise capacity or clinical status in patients with symptomatic heart failure (HF) and preserved ejection fraction, according to a JAMA study. This finding contrasts with previous research suggesting a potential benefit in such patients. Some 220 HF patients with ejection fractions of 50% or greater were randomized to receive oral sildenafil or […]

March 4th, 2013

Selections from Richard Lehman’s Literature Review: March 4th

This week’s topic is the ALDO-DHF trial, which studied the effect of spironolactone on diastolic function and exercise capacity in patients with HF with preserved EF.

February 26th, 2013

Mixed Results for Spironolactone in Heart Failure with Preserved Ejection Fraction

Although the mineralocorticoid receptor antagonists spironolactone and eplerenone have been shown to be beneficial in patients with heart failure (HF) with reduced ejection fraction (EF), their role in  HF patients with preserved EF has not been tested until now. Now the results of the Aldo-DHF study (Aldosterone Receptor Blockade in Diastolic Heart Failure), published in […]